AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DURVALUMAB IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER TREATMENT WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Guillermo Garcia-Manero, 215548
SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK
EHA Learning Center, Uwe Platzbecker, 215549
HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
EHA Learning Center, Liat shargian-alon, 215550
RESPONSE TO HYPOMETHYLATING AGENTS IMPROVES LONG-TERM OUTCOMES FOR LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROME IN CASE-MATCHED COHORTS
EHA Learning Center, Dongwon Baek, 215551
A SYSTEMATIC REVIEW PROVIDES LIMITED CLINICAL EVIDENCE FOR ADDITIONAL EFFICACY OF G-CSF + ESA COMPARED TO FULL-DOSE ESA ALONE IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW-RISK MDS
EHA Learning Center, Lucas Affentranger, 215552
LOW RISK MDS WITHOUT RING SIDEROBLASTS. CLINICAL AND BIOLOGICAL CHARACTERIZATION FROM THE SPANISH GROUP OF MDS.
EHA Learning Center, Félix López Cadenas, 215553
SEROTONIN RECEPTOR TYPE 1B CONSTITUTES A THERAPEUTIC TARGET FOR MDS AND CMML.
EHA Learning Center, Antònia BANÚS MULET, 215554
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
EHA Learning Center, Paola Strati, 215555
FETAL HEMOGLOBIN INDUCTION DURING DECITABINE TREATMENT OF ELDERLY MDS/AML PATIENTS: A POTENTIAL DYNAMIC BIOMARKER FOR OUTCOME
EHA Learning Center, Julia Stomper, 215556
CLINICAL IMPACT ON THE THERAPEUTIC STRATEGY ADAPTED TO THE MUTATIONAL PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL(5Q)
EHA Learning Center, Carolina Alarcón-Payer, 215557
CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY.
EHA Learning Center, Panagiotis Diamantopoulos, 215558
OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND STABLE DISEASE DURING TREATMENT WITH AZACITIDINE: A REPORT FROM GRUPPO ROMANO MIELODISPLASIE (GROM) AND RETE EMATOLOGICA LOMBARDA (REL).
EHA Learning Center, Luca Maurillo, 215559
PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM
EHA Learning Center, Marcelo Iastrebner, 215560
IRON SUPPORT ENHANCES ERYTHROPOIETIN EFFECTIVENESS IN REFRACTORY ANEMIA WITH HIGH RETICULOCYTE COUNT, TRANSFERRIN SATURATION BELOW 30% AND HIGH LEVEL OF ERYPTOSIS.
EHA Learning Center, GIULIO GIORDANO, 215561
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
EHA Learning Center, Carolina Lazzarino, 215563
TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA
EHA Learning Center, Cesarina Giallongo, 215564
BI-ALLELIC LOSS OF FAM46C BY CRISPR/CAS9 SYSTEM ENHANCES MYELOMA CELL GROWTH
EHA Learning Center, KANASUGI JO, 215565
MOLECULAR SEGMENTATION OF MULTIPLE MYELOMA BY INTEGRATIVE MULTI-OMICS ANALYSIS
EHA Learning Center, Maria Ortiz Estevez, 215566
SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA
EHA Learning Center, Muntasir Majumder, 215567
ADAR1-MEDIATED-NEIL1 EDITING IS OF BIOLOGICAL SIGNIFICANCE IN MULTIPLE MYELOMA
EHA Learning Center, Phaik Ju Teoh, 215568
IRON INCREASES THE EFFICACY OF STANDARD MULTIPLE MYELOMA THERAPY IN TRANSGENIC VK*MYC MODEL
EHA Learning Center, Jessica Bordini, 215569
BONE MARROW MACROPHAGES IN PATIENTS WITH MULTIPLE MYELOMA IN COMPLETE REMISSION RETAIN PRO-TUMOR M2 PHENOTYPE
EHA Learning Center, Ester Lozano, 215570
PTC-028 DEMONSTRATES POTENT PRE-CLINICAL ACTIVITY AND PROVIDES A NOVEL OPPORTUNITY TO MODULATE BMI1 IN MULTIPLE MYELOMA
EHA Learning Center, Heinz Ludwig, 215571
ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA
EHA Learning Center, Alessandra Romano, 215572
DEMETHYLATION SENSITISES T(4;14) MULTIPLE MYELOMA TO RAS-MAPK PATHWAY INHIBITION
EHA Learning Center, Jay Hocking, 215573
CD96 (TACTILE) NEGATIVELY REGULATES THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA
EHA Learning Center, Michael O'Dwyer, 215574
GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION
EHA Learning Center, Paola Minetto, 215575
MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN MULTIPLE MYELOMA RESISTANCE
EHA Learning Center, Alejandra Ortiz, 215576
ELOTUZUMAB PROMOTES SELF-ENGAGEMENT OF SLAMF7 BETWEEN NATURAL KILLER AND MULTIPLE MYELOMA CELLS TO ENHANCE CYTOTOXICITY
EHA Learning Center, Michael D. Robbins, 215577
CARFILZOMIB-INDUCED CARDIOTOXICITY: MOLECULAR MECHANISMS AND THE EMERGING ROLE OF METFORMIN AS A PROPHYLACTIC THERAPY
EHA Learning Center, Evangelos Terpos, 215578
JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA
EHA Learning Center, Maria Teresa Palano, 215579
TGFΒ INHIBITION IN COMBINATION WITH CHEMOTHERAPY REPAIRS EXISTING LYTIC BONE LESIONS IN A NOVEL PLATEAU PHASE MODEL OF MULTIPLE MYELOMA
EHA Learning Center, Andrew Chantry, 215580
MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.
EHA Learning Center, Vittorio Emanuele Muccio, 215581
MULTIPLE MYELOMA PATHOGENESIS: THE ROLE OF JUNB IN BONE MARROW ANGIOGENESIS
EHA Learning Center, Stefano Malvestiti, 215582
TARGETED LIPOSOMAL MULTI-DRUG DELIVERY TO TUMOR-ASSOCIATED ENDOTHELIUM AS A NOVEL STRATEGY TO REVERSE MICROENVIRONMENT-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA
EHA Learning Center, Cinzia Federico, 215583
WNT/Β-CATENIN AND HEDGEHOG INHIBITORS AS THERAPEUTIC APPROACHES IN B-CELL NEOPLASMS
EHA Learning Center, Ana Bela Sarmento Ribeiro, 215584
MULTIPLE MYELOMA INDUCES CHANGES IN BONE MARROW ADIPOCYTES IN VITRO AND IN VIVO
EHA Learning Center, Michaela Reagan, 215585
PROTEIN KINASE CK1 ALPHA MODULATES PROSURVIVAL AUTOPHAGY IN MULTIPLE MYELOMA
EHA Learning Center, Marilena Carrino, 215586
SERUM LIPID METABOLOMICS AS AN USEFUL BIOMARKER PREDICTING FOR THE EFFICACY OF BORTEZOMIB TREATMENT AND PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA
EHA Learning Center, Masaki Ri, 215587
CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY
EHA Learning Center, Evangelos Terpos, 215588
PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM’S MACROGLOBULINEMIA
EHA Learning Center, Antonio Sacco, 215589
EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS
EHA Learning Center, Joan Ballesteros, 215590
ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL
EHA Learning Center, Matthew Jenner, 215591
POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE-BASED TREATMENT FAILURE
EHA Learning Center, David S. Siegel, 215592
DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)
EHA Learning Center, Sara Bringhen, 215593
POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN CASE OF SUBOPTIMAL RESPONSE TO POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: RESULTS OF THE GMMG-PERSPECTIVE TRIAL
EHA Learning Center, Katja C Weisel, 215594
SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Rowan Kuiper, 215595
CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)
EHA Learning Center, Chandramouli Nagarajan, 215596
WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY
EHA Learning Center, Noa Biran, 215597
EXTENDED 5-Y FOLLOW-UP OF PHASE 3 ELOQUENT-2 STUDY: ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Katja C Weisel, 215598
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.
EHA Learning Center, Francesca Gay, 215599
A GLOBAL TREATMENT STANDARD IN MULTIPLE MYELOMA (MM) REMAINS ELUSIVE DESPITE ADVANCES IN CARE OVER 15 YEARS: FIRST RESULTS FROM INSIGHT MM, THE LARGEST GLOBAL PROSPECTIVE, OBSERVATIONAL MM STUDY
EHA Learning Center, Mario Boccadoro, 215600
TREATMENT AND SURVIVAL OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY AMONG 179 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 TO 2015
EHA Learning Center, Avinash Dinmohamed, 215601
NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A BIOMARKER IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: DATA FROM A PHASE II TRIAL OF POMALIDOMIDE PLUS DEXAMETHASONE
EHA Learning Center, Katja Weisel, 215602
REAL WORLD CLINICAL IMPLICATIONS OF THE LIMITATIONS ASSOCIATED WITH THE REVISED INTERNATIONAL STAGING SYSTEM: UNSELECTED PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NOVEL AGENTS IN AGEING SOCIETY
EHA Learning Center, Yoshiaki Abe, 215603
EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Ioannis Kostopoulos, 215604
EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS
EHA Learning Center, Gregory Kaufman, 215605
EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA.
EHA Learning Center, Ana González Rodríguez, 215606
CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN NORTH AMERICA AND EUROPE: FINDINGS FROM THE PREAMBLE STUDY
EHA Learning Center, Ravi Vij, 215607
COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015
EHA Learning Center, Annette Vangsted, 215608
OVERALL SURVIVAL OF PATIENTS POST-TRANSPLANT: STUDY RESULTS FROM TWO PHASE 3 TRIALS ASPIRE AND ENDEAVOR
EHA Learning Center, Hartmut Goldschmidt, 215609
DURABLE PROGRESSION-FREE SURVIVAL BENEFIT IN EARLY RESPONDERS TO ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF 4-YEAR DATA FROM ELOQUENT-2
EHA Learning Center, Christof Scheid, 215610
SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA
EHA Learning Center, Marcella Tschautscher, 215611
NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY
EHA Learning Center, Mauricette Michallet, 215612
REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT
EHA Learning Center, FAOUZI DJEBBARI, 215613
BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME
EHA Learning Center, Luis Gerardo Rodríguez-Lobato, 215614
TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE
EHA Learning Center, Richa Manwani, 215615
TANDEM TRANSPLANTATION OVERCOMES POOR PROGNOSIS IN NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA WITH HIGH-RISK CYTOGENETICS: A RETROSPECTIVE STUDY BY THE CMWP-EBMT
EHA Learning Center, Nico Gagelmann, 215616
VENETOCLAX MONOTHERAPY AND COMBINED WITH DEXAMETHASONE AS TARGETED THERAPY FOR RELAPSED/REFRACTORY T(11;14) MULTIPLE MYELOMA
EHA Learning Center, Jonathan Kaufman, 215617
SUBCUTANEOUS DARATUMUMAB (DARA SC) + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: SAFETY RUN-IN RESULTS OF ANDROMEDA
EHA Learning Center, Giampaolo Merlini, 215618
DISEASE ASSESSMENT BY PET-CT PLUS FLOW CYTOMETRY IN MULTIPLE MYELOMA IDENTIFIES PATIENTS WITH DIFFERENT SURVIVAL OUTCOMES
EHA Learning Center, Rafael Alonso Fernández, 215619
PREDICTORS OF HEMATOLOGIC AND ORGAN RESPONSE IN AL AMYLOIDOSIS
EHA Learning Center, Giovanni Palladini, 215620
IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Heinz Ludwig, 215621
SELINEXOR COMBINED WITH LOW DOSE BORTEZOMIB AND DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)
EHA Learning Center, Nizar Bahlis, 215622
THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS
EHA Learning Center, Tobias Klausen, 215623
COMPARISON OF LYMPHOTRACK® MISEQ® ASSAYS AND FLOW CYTOMETRY FOR CLONALITY AND MINIMUM RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA
EHA Learning Center, Austin Jacobsen, 215624
QUALITY OF HEMATOLOGIC RESPONSE BUT NOT DEPTH OF NT-PROBNP RESPONSE IMPROVES SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS WHO ACHIEVE CARDIAC RESPONSE
EHA Learning Center, Paolo Milani, 215625
SUSTAINED MRD NEGATIVITY AT 12 MONTHS POST-ASCT PREDICTS OUTCOMES FOR MYELOMA PATIENTS: A REAL WORLD STUDY.
EHA Learning Center, Michael Austin, 215626
MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM).
EHA Learning Center, Alexis Caulier, 215627
AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).
EHA Learning Center, Michaela Kotrová, 215628
A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
EHA Learning Center, Cristina Gasparetto, 215629
A REAL WORLD RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: CLINICAL FEATURES AND OUTCOME
EHA Learning Center, Meral BEKSAC, 215630
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN AL AMYLOIDOSIS: SURVIVAL IMPROVEMENT IN DIFFERENT RISK CATEGORIES IN A SINGLE CENTER EXPERIENCE

EHA Learning Center, Angelo Belotti, 215631
COMPARABLE OUTCOMES USING PROPYLENE GLYCOL-FREE MELPHALAN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
EHA Learning Center, Kevin Miller, 215632
ACTIVITY AND SAFETY OF DARATUMUMAB MONOTHERAY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA REQUIRING DIALYSIS: PRELIMINARY RESULTS OF A SPANISH, RETROSPECTIVE, MULTICENTER TRIAL
EHA Learning Center, Maria Jose cejalvo, 215633
OPTIMISING TREATMENT FOR HIGH-RISK MYELOMA IN A STRATIFIED MULTI-CENTRE TRIAL: EXPERIENCE FROM MUKNINE OPTIMUM STUDY
EHA Learning Center, Martin Kaiser, 215634
ASYMPTOMATIC HEART INVOLVEMENT IN AL AMYLOIDOSIS
EHA Learning Center, Marco Basset, 215635
RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS
EHA Learning Center, Dorothy Romanus, 215636
PHARMACOKINETIC EVALUATION OF TEST DOSE PREDICTIONS OF HIGH DOSE MELPHALAN EXPOSURE IN PATIENTS WITH MULTIPLE MYELOMA.
EHA Learning Center, Judith Trotman, 215637
A PHASE II STUDY OF SELINEXOR(KPT-330) COMBINED WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR INDUCTION AND CONSOLIDATION FOR PATIENTS WITH PROGRESSIVE OR REFRACTORY MULTIPLE MYELOMA: THE SELVEDEX TRIAL
EHA Learning Center, A Broijl, 215638
LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Qaiser Bashir, 215639
THE SCREENING OF PROTEINS SIGNATURES WITH SIGNALING PATHWAY IN POLYCYTHEMIA VERA AND INHIBITION OF PIM ENHANCES JAK2 INHIBITOR SENSITIVITY
EHA Learning Center, Wuhan Hui, 215640
IMPACT OF MOLECULAR ANALYSIS ON PROGNOSTIC SCORES IN ESSENTIAL THROMBOCYTHEMIA: A SINGLE CENTER PROSPECTIVE COHORT EXPERIENCE
EHA Learning Center, Damien Luque Paz, 215641
THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Kira Behrens, 215642
BOARDING ON THE SECRETARY PATHWAY IS REQUIRED FOR THE ONCOGENIC PROPERTY OF MUTANT CALRETICULIN
EHA Learning Center, Marito Araki, 215643
PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Jaqueline Cristina Fernandes, 215644
IN VIVO INHIBITION OF JAKS IN MYELOFIBROSIS IMPROVES MONOCYTES DIFFERENTIATION AND REACTIVATES PRO-INFLAMMATORY RESPONSE IN INFECTION-STIMULATED MONOCYTES
EHA Learning Center, Lucia Catani, 215645
POLO-LIKE KINASE-1, AURORA KINASE A AND WEE1: NEW THERAPEUTIC TARGETS IN SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Manuela Mancini, 215646
NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS
EHA Learning Center, Alfio Bonanno, 215647
POSSIBLE SOMATIC MOSAICISM OF THE JAK2 GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Naoki Mori, 215648

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings